Oncodesign, Covalab, CheMatech and ABX-CRO launch DRIVE™-MRT
A premium complete, integrated service offer for radiopharmaceuticals drug discovery and generation
The process of discovery and development of a molecule is complex, long and costly. Before making a decision on the offer that best meets your needs, we offer online scientific resources and our latest news to help you get to know us better. Our experts are also at your disposal to help and support you in your research and development program.
Filter by BU or service
- All
- Corporate
- Service
- Biotech
- A.I
- Homing program
- Financial
- HR
Filter by BU or service
Filter by category
- All
- Webinar
- Posters
- Scientific publications
- Press release
- Press coverage
- Media kit
- News
Filter by category
Scientific resources
Webinar
Service
Service
Posters
Service
Biotech
01/09/2020
NANOCYCLIX® ALK2 INHIBITORS TO OVERCOME CANCER INDUCED ANEMIA
NANOCYCLIX® ALK2 INHIBITORS TO OVERCOME CANCER INDUCED ANEMIA
Biotech
31/03/2019
Nanocyclix: next generation kinase therapeutics A chemocentric approach for the discovery of selective kinase inhibitors
Nanocyclix: next generation kinase therapeuticsA chemocentric approach for the discovery of selective kinase inhibitors
Scientific publications
Service
04/09/2021
Nafamostat–Interferon-α Combination Suppresses SARS-CoV-2 Infection In Vitro and In Vivo by Cooperatively Targeting Host TMPRSS2
SARS-CoV-2; interferon-alpha; nafamostat; antiviral drug combination; broad-spectrum antivirals
Service
04/09/2021
Nafamostat-Interferon-α Combination Suppresses SARS-CoV-2 Infection In Vitro and In Vivo by Cooperatively Targeting Host TMPRSS2
SARS-CoV-2; antiviral drug combination; broad-spectrum antivirals; interferon-alpha; nafamostat.
Biotech
12/06/2021
Inhibiting Endothelial Cell Function in Normal and Tumor Angiogenesis Using BMP Type I Receptor Macrocyclic Kinase Inhibitors
Inhibiting Endothelial Cell Function in Normal and Tumor Angiogenesis Using BMP Type I Receptor Macrocyclic Kinase Inhibitors
Service
19/05/2021
Exploring the Complementarity of Pancreatic Ductal Adenocarcinoma Preclinical Models
Exploring the Complementarity of Pancreatic Ductal Adenocarcinoma Preclinical Models
Service
01/04/2021
Antitumor Activity of Eribulin After Fulvestrant Plus CDK4/6 Inhibitor in Breast Cancer Patient-derived Xenograft Models
Antitumor Activity of Eribulin After Fulvestrant Plus CDK4/6 Inhibitor in Breast Cancer Patient-derived Xenograft Models
Biotech
24/10/2014
In vivo inhibition of RIPK2 kinase alleviates inflammatory disease
In vivo inhibition of RIPK2 kinase alleviates inflammatory disease
Press
Press release
Corporate
Financial
25/10/2021
Oncodesign has appointed Karine Lignel as Group Chief Development Officer
Oncodesign adds a new high-level competence to its COMEX to achieve its external growth objectives with Karine Lignel.
Corporate
Financial
25/10/2021
Oncodesign has appointed Karine Lignel as Group Chief Development Officer
Oncodesign adds a new high-level competence to its COMEX to achieve its external growth objectives with Karine Lignel.
Biotech
21/10/2021
Oncodesign and TiumBio sign collaboration agreement for R&D of fibrosis drug candidates
Under this agreement, Oncodesign will be responsible for identification, chemical synthesis & optimization of Nanocyclix® drug candidates & their early-stage analysis. TiumBio will be responsible for the advanced evaluation of fibrotic efficacy of the drug candidates.
Financial
16/09/2021
Oncodesign announces its results for the first half of 2021
Read all the financial information of Oncodesign and its Business Units Service, Biotech and Artificial Intelligence.
Financial
21/07/2021
Oncodesign announces a sharp increase in turnover in the first half of 2021
Group turnover up by 33% at €15.8M. Despite the global health crisis, which continues to limit international travel...
Corporate
Financial
05/07/2021
Oncodesign announces the appointment of Aline Aubertin as an independent director of the Board of Directors
Oncodesign strenghens its Board by appointing Aline Aubertin as new independent director.
Corporate
Financial
05/07/2021
Oncodesign announces the appointment of Aline Aubertin as an independent director of the Board of Directors
Oncodesign strenghens its Board by appointing Aline Aubertin as new independent director.
Service
01/07/2021
Oncodesign, Covalab, CheMatech and ABX-CRO launch DRIVE™-MRT
Discover the alliance of experts in radiopharmaceuticals: an innovative offer in therapeutic development in nuclear medicine from the validation of therapeutic targets, the generation of radiolabeled biological vectors, the optimization of leads, the generation of drug candidates to IND, the design and management of clinical trials.
Service
Financial
Oncodesign launches its new DRIVE-MRT™ service offer in partnership with Covalab, CheMatech and ABX-CRO
[Press Release] Explore our brand new service offer DRIVE-MRT. it allows the rationalization, design and optimization of targeted radiopharmaceutical products that are effective against certain metastatic cancers.
Biotech
Financial
24/06/2021
Oncodesign provides an update on its progress on RIPK2
[Press Release] Find the update of the RIPK2 program and the start of new programs associated with Nanocyclix.
Corporate
Service
Service partnership agreement between Oncodesign and Galderma
Press Release: Multi-year service contract: design and discover new drug candidates in dermatology - Galderma.
Corporate
Service
Service partnership agreement between Oncodesign and Galderma
Press Release: Multi-year service contract: design and discover new drug candidates in dermatology - Galderma.
Corporate
Service
Centre Georges François Leclerc Presents the Detailed Results of the First Two Stages of its Clinical Study in Lung Cancer at the EANM Congress
Presentation of detailed results from the first two stages of the clinical trial in lung cancer | 31st EANM1 | 2018.
Corporate
Service
Centre Georges François Leclerc Presents the Detailed Results of the First Two Stages of its Clinical Study in Lung Cancer at the EANM Congress
Presentation of detailed results from the first two stages of the clinical trial in lung cancer | 31st EANM1 | 2018.
Corporate
A.I
Precision medicine: Cap Digital and Medicen Paris-Region team-up with Oncodesign, Servier and Intersystems on Hu-PreciMED
Hu-PreciMED project will gear French precision medicine industry towards discovering new diagnostic approaches & novel therapeutic treatments.
Press coverage
Financial
Corporate
Biotech
Corporate
Biotech
Corporate
Biotech
Biotech
Corporate
Corporate
Media kit
Corporate
News
Corporate
Financial
25/10/2021
Oncodesign has appointed Karine Lignel as Group Chief Development Officer
Oncodesign adds a new high-level competence to its COMEX to achieve its external growth objectives with Karine Lignel.
Biotech
21/10/2021
Oncodesign and TiumBio sign collaboration agreement for R&D of fibrosis drug candidates
Under this agreement, Oncodesign will be responsible for identification, chemical synthesis & optimization of Nanocyclix® drug candidates & their early-stage analysis. TiumBio will be responsible for the advanced evaluation of fibrotic efficacy of the drug candidates.
20/10/2021
[WEBINARS] Pharmaco-imaging, COVID-19, Microbiome…
[Webinars] Radiopharmaceutics, COVID-19, Microbiome… join us this fall during a webinar
Service
19/10/2021
[CONGRESS] Discovery UK: 26 – 27 October 2021
Oncodesign will be at the in-person event by Oxford Global in London, Discovery UK.
Financial
16/09/2021
Oncodesign announces its results for the first half of 2021
Read all the financial information of Oncodesign and its Business Units Service, Biotech and Artificial Intelligence.
Corporate
Financial
05/07/2021
Oncodesign announces the appointment of Aline Aubertin as an independent director of the Board of Directors
Oncodesign strenghens its Board by appointing Aline Aubertin as new independent director.
Corporate
02/07/2021
Find out how we built our logo!
Oncodesign Find out how we built our logo! trajectory DNA innovation...green and bleue pharma colors Find out how we built our logo!
Corporate
01/07/2021
Brand new logo for Oncodesign
Brand new logo for Oncodesign. New graphic identity with evolutive look & feel approach... First element of our new logo.
Biotech
Financial
24/06/2021
Oncodesign provides an update on its progress on RIPK2
[Press Release] Find the update of the RIPK2 program and the start of new programs associated with Nanocyclix.
Service
23/06/2021
[Congress] Microbiome movement Drug Development Summit June 29 – July 1, 2021
Listen to our expert talk about “preclinical solutions for microbiome investigation in pathological situation and drug development”
Service
07/10/2019
[EN] [Congress] Start.Smart.Global 2019 – 7-10 October 2019: Roadshow in Japan & November 2019: Roadshow in South Korea
RoadShow in Japan and South Korean to demonstrate the potency and specificity of our innovative technology module Nanocyclix®
Corporate
Financial
Corporate
Financial
Corporate
Service
Corporate
Financial
Corporate
Our brand Oncodesign
Our brand Oncodesign . Combination of the words oncology and design... Precision Medicine for patient... Oncodesign
There are no resources available for your request. Contact us directly via our contact form for any information request